Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

Michael Y. Choi,1 George F. Widhopf II,1 Christina C.N. Wu,1 Bing Cui,1 Fitzgerald Lao,1 Anil Sadarangani,1,2 Joy Cavagnaro,3 Charles Prussak,1 Dennis A. Carson,1 Catriona Jamieson,1,2 Thomas J. Kipps1

Abstract

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a type I surface protein expressed during embryogenesis, where it contributes polarized migration and organogenesis.1-3 It contains a transmembrane domain, a cytoplasmic tyrosine kinase-like domain, and extracellular ligand binding domains, including a cysteine-rich domain homologous to Frizzled receptors for various Wnt factors.2 The expression of ROR1 is developmentally regulated. Expression of ROR1 attenuates during fetal development and becomes negligible at term. Normal postpartum tissues lack surface expression of the ROR1 protein, with the exception of hematogones.4

Gene expression studies identified distinctive expression of ROR1 in chronic lymphocytic leukemia (CLL) cells, in contrast to normal B lymphocytes.5,6 Analysis of autoantibodies produced by patients immunized with autologous leukemia cells transduced to express CD154 identified that these autoantibodies recognized ROR1 protein on the leukemia cell surface.7 Functional studies found that ROR1 could serve as a receptor for Wnt5a, which induces noncanonical Wnt signaling, leading to enhanced leukemia cell survival; also anti-ROR1 antibodies produced by some patents could neutralize the prosurvival effects of Wnt5a on leukemia cells in vitro.7 Downstream signaling from ROR1 apparently activates the phosphoinositide 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin pathway,8,9 and studies in other cancer cell lines suggest that ROR1 might be a pseudokinase that serves as a substrate for other signaling molecules, such as Met proto-oncogene (MET), also known as hepatocyte growth factor receptor.10,11

Receptor Tyrosine Kinase-Like Orphan Receptor 1-Targeted Therapies and Derivation of UC-961

Because of its tumor specific expression and potential functional significance, ROR1 has been of interest as a target for novel immunotherapies. An early report of anti-ROR1 monoclonal antibodies (mAbs) screened using phage display for optimal binding found that these mAbs typically bound the N-terminal region of the extracellular immunoglobulin-like domain of ROR1, but had limited direct cytotoxicity for human CLL cells.12 One of these mAbs (designated 2A2) is currently under exploration as a part of antibody drug conjugates or chimeric antigen receptor-expressing T-cells.13-16
Preclinical Specificity and Safety of Cirtmuzumab

However, other groups have produced naked mAbs capable of directly inducing apoptosis of CLL cells. We screened hybridomas for production of mAbs mimicking the activity of anti-ROR1 autoantibodies that we observed in some patients vaccinated against autologous leukemia cells. We also examined the activity of various mAbs in vivo using a ROR1 transgenic mouse model of CLL. We identified one mAb, D10, of relatively low affinity that could inhibit activation of AKT and engraftment of ROR1-positive (ROR1⁺) leukemia cells in this model. Mapping the epitope bound by this mAb allowed us to generate mAbs of substantially higher affinity for ROR1 that retained this distinctive biologic activity. We humanized the variable regions of one such mAb (designated UC-961, or cirtmuzumab), which maintained high binding affinity (Dissociation constant = 2 nM) for the functional epitope of ROR1.

Preclinical Specificity and Safety Studies of UC-961

Studies with other anti-ROR1 mAbs have found potential expression of ROR1 on adipose tissue and pancreatic islet cells. Therefore, we performed a Good Laboratory Practice-compliant human tissue cross-reactivity study with UC-961 before proceeding with clinical testing of this mAb. Samples from all human tissues from 3 separate donors were probed with UC-961 at the concentrations up to 5 times the optimal staining concentration for ROR1⁺ cancer tissue. We did not observe any cross-reactivity with normal postpartum tissues, including the pancreas or adipose tissue (Figure 1).

We conducted rodent and primate studies to assess for off-target or non-ROR1-specific activity. Groups of Sprague-Dawley rats (15 of each sex) received UC-961 at doses of 40 to 400 mg/kg using intravenous (I.V.) administration weekly for 5 doses over 28 days. Clinical signs, body weight, clinical pathology, and safety pharmacology measurements were assessed during the study. Twenty animals (10 of each sex) in each dosing cohort were sacrificed 3 days after the final UC-961 injection, and the remaining animals were sacrificed on day 56. In all groups, UC-961 was well tolerated and no adverse effects were noted. At terminal sacrifice, gross pathologic...
examinations were normal and no untoward pathology was observed. We also performed studies in cynomolgus monkeys. UC-961 was administered once using I.V. injection at a dosage of 40 mg/kg. There were no changes in body weight, clinical chemistry values, or hematologic parameters, including absolute numbers of T or B cells. Pharmacokinetic evaluation of plasma samples indicated the elimination half-life of UC-961 was > 14 days.

**Discussion**

Monoclonal antibodies are effective agents in the therapy of patients with CLL or other cancers. Treatment of patients with mAbs has provided prolonged survival alone or in combination with chemotherapy. To date, mAbs currently used in the therapy of patients with CLL are mostly directed against CD20, an antigen also found on normal B cells. As such, treatment with such mAbs can cause depletion of normal B cells and potentially enhance posttreatment hypogammaglobulinemia. Agents directed against CD19, CD37, CD52, or other antigens also are being evaluated. However, none of these antigens are unique to CLL cells, potentially limiting their therapeutic index by targeting noncancer cells, resulting in immune suppression or other risks. Targeting ROR1 might be advantageous because it is a tumor-specific antigen that has functional importance to CLL cells.

UC-961 targets a distinctive epitope of ROR1 and has biologic activity against ROR1+ tumor cells. Preclinical studies did not detect toxicity. This might be because UC-961 does not have detectable binding activity for normal postpartum tissues. However, human trials will be necessary to determine the safety and activity of this mAb in the therapy for patients with CLL. To this end, a phase I trial is currently enrolling (NCT02222688). This also will provide another opportunity to evaluate the functional effect of targeting ROR1 on CLL in vivo.

The implications of this work extend beyond CLL. ROR1 is broadly expressed in many types of cancer and not their normal tissue counterparts. Although the prevalence of ROR1 expression in solid tumors does not appear to be as high as it is in CLL, its expression is found in cancers that are poorly differentiated and that in high relapse rates and high metastatic potential. More recent studies have identified ROR1 on the cancer stem cells in ovarian cancer. Moreover, treatment of immune-deficient mice engrafted with ovarian cancer patient-derived xenografts (PDX) with UC-961 could induce senescence in the cancer stem cells, thereby inhibiting the growth of the ovarian cancer PDX and its capacity to re-engraft other immune-deficient mice. As such, UC-961 might have broader applications in the treatment of patients with solid-tumor malignancies in addition to the treatment of patients with CLL.

**Clinical Practice Points**

- ROR1 is an oncoembryonic protein that is expressed by a variety of human cancers, including CLL, but not by normal adult tissue.
- UC-961 (Cirtuzumab) is a first-in-class ROR1-targeted monoclonal antibody that binds to and has functional activity against cancer cells, but NOT against normal adult tissues.
- We did not observe UC-961 to have any off-target activity or toxicity in preclinical tests.
- We currently are conducting a Phase 1 study of UC-961 in patients with relapsed or refractory CLL.

**Disclosure**

Conflicts of interest: none. Financial support for the conduct of the research was provided by the Leukemia Lymphoma Society (SCOR 7005-14), the National Institutes of Health grant for the CLL Research Consortium (P01-CA081534), and the California Institute of Regenerative Medicine (DR-06924).

**References**